TY  - JOUR
AU  - Radak, Đorđe J.
AU  - Đukić, Nenad
AU  - Tanasković, Slobodan
AU  - Obradović, Milan M.
AU  - Cenić-Milošević, Desanka
AU  - Isenović, Esma R.
PY  - 2017
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1522
AB  - Endovascular surgery represents a minimally invasive procedure for the treatment of occlusive and aneurysmal arterial disease. However, it is followed by inflammatory response, with a rise in specific inflammatory biomarkers, such as C-reactive protein, serum amyloid A and fibrinogen. Shear stress during balloon inflation and vascular injury represents triggering events for the inflammatory process, stimulating the production of proinflammatory molecules and activation of circulating monocytes. The current literature indicates that stent implantation induces more prominent inflammatory reaction. Additionally, it has been shown that muscular arteries of femoropopliteal segment react to a greater extent to stent implantation, compared with elastic carotid or iliac arteries. The endovascular treatment of thoracic and abdominal aortic aneurysm is frequently followed with post-implantation inflammatory syndrome. Most recent findings point out that stent graft material plays a significant role in the inflammatory response, representing a challenge for clinicians. Future studies should consider the pathophysiology of the inflammatory response associated with endovascular procedures as well as predictors and risk factors including preventive strategies and therapeutic algorithms. Although the potential role of anti-inflammatory drugs after endovascular procedures has been observed, it needs to be validated in upcoming trials. The Neutrophil Lymphocyte Ratio, platelet count, Platelet-to-Lymphocyte Ratio and other biomarkers should be considered in future trials to assess the inflammatory response after endovascular procedures. Inflammatory markers may also become therapeutic targets.
T2  - Current Vascular Pharmacology
T1  - Should We be Concerned About the Inflammatory Response to Endovascular Procedures?
VL  - 15
IS  - 3
SP  - 230
EP  - 237
DO  - 10.2174/1570161115666170105121900
ER  - 

@article{
author = "Radak, Đorđe J. and Đukić, Nenad and Tanasković, Slobodan and Obradović, Milan M. and Cenić-Milošević, Desanka and Isenović, Esma R.",
year = "2017",
abstract = "Endovascular surgery represents a minimally invasive procedure for the treatment of occlusive and aneurysmal arterial disease. However, it is followed by inflammatory response, with a rise in specific inflammatory biomarkers, such as C-reactive protein, serum amyloid A and fibrinogen. Shear stress during balloon inflation and vascular injury represents triggering events for the inflammatory process, stimulating the production of proinflammatory molecules and activation of circulating monocytes. The current literature indicates that stent implantation induces more prominent inflammatory reaction. Additionally, it has been shown that muscular arteries of femoropopliteal segment react to a greater extent to stent implantation, compared with elastic carotid or iliac arteries. The endovascular treatment of thoracic and abdominal aortic aneurysm is frequently followed with post-implantation inflammatory syndrome. Most recent findings point out that stent graft material plays a significant role in the inflammatory response, representing a challenge for clinicians. Future studies should consider the pathophysiology of the inflammatory response associated with endovascular procedures as well as predictors and risk factors including preventive strategies and therapeutic algorithms. Although the potential role of anti-inflammatory drugs after endovascular procedures has been observed, it needs to be validated in upcoming trials. The Neutrophil Lymphocyte Ratio, platelet count, Platelet-to-Lymphocyte Ratio and other biomarkers should be considered in future trials to assess the inflammatory response after endovascular procedures. Inflammatory markers may also become therapeutic targets.",
journal = "Current Vascular Pharmacology",
title = "Should We be Concerned About the Inflammatory Response to Endovascular Procedures?",
volume = "15",
number = "3",
pages = "230-237",
doi = "10.2174/1570161115666170105121900"
}

Radak, Đ. J., Đukić, N., Tanasković, S., Obradović, M. M., Cenić-Milošević, D.,& Isenović, E. R.. (2017). Should We be Concerned About the Inflammatory Response to Endovascular Procedures?. in Current Vascular Pharmacology, 15(3), 230-237.
https://doi.org/10.2174/1570161115666170105121900

Radak ĐJ, Đukić N, Tanasković S, Obradović MM, Cenić-Milošević D, Isenović ER. Should We be Concerned About the Inflammatory Response to Endovascular Procedures?. in Current Vascular Pharmacology. 2017;15(3):230-237.
doi:10.2174/1570161115666170105121900 .

Radak, Đorđe J., Đukić, Nenad, Tanasković, Slobodan, Obradović, Milan M., Cenić-Milošević, Desanka, Isenović, Esma R., "Should We be Concerned About the Inflammatory Response to Endovascular Procedures?" in Current Vascular Pharmacology, 15, no. 3 (2017):230-237,
https://doi.org/10.2174/1570161115666170105121900 . .